Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Number of holders
-
200
-
Total 13F shares, excl. options
-
87,967,283
-
Shares change
-
-1,023,041
-
Total reported value, excl. options
-
$1,615,322,964
-
Value change
-
-$17,575,985
-
Put/Call ratio
-
217%
-
Number of buys
-
111
-
Number of sells
-
-83
-
Price
-
$18.34
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q3 2020
229 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q3 2020.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 200 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87,967,283 shares
of 116,964,738 outstanding shares and own 75% of the company stock.
Largest 10 shareholders include BlackRock Inc. (10,210,732 shares), Temasek Holdings (Private) Ltd (7,381,116 shares), JPMORGAN CHASE & CO (4,730,357 shares), ALLIANCEBERNSTEIN L.P. (4,511,239 shares), STATE STREET CORP (4,294,406 shares), VANGUARD GROUP INC (3,866,529 shares), PERCEPTIVE ADVISORS LLC (3,636,485 shares), Kohlberg Kravis Roberts & Co. L.P. (3,036,076 shares), AMERIPRISE FINANCIAL INC (2,365,728 shares), and Camber Capital Management LP (2,200,000 shares).
This table shows the top 200 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.